"The data submitted in this NDA support the use of sofosbuvir and ribavirin (RBV) as an all-oral therapy for patients with genotype 2 and 3 HCV infection, and for sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) for treatment-naïve patients with genotype 1, 4, 5 and 6 HCV infection."
So after all the hype by GILD and the clueless analysts, Gild's miracle drug still has to be used with IFN for the majority of patients (genotype 1's). It is just amazing how stupid things are on wall street.
With all due respect, I don't think "failure" is the word that comes to mind. A brilliant management team bought essentially a single molecule at an incredibly rich price and doubled their share price over the last year. Whether it fulfills it's promise(or lack of) would you rather have been long Vertex or Gilead over the past year? While I believe Vertex is incredibly undervalued with either or both VX-809 and VX-661 a lock for approval( and the rest of the pipeline compelling) it is mind boggling how inept management is at convincing anyone other than the regular posters here of the same.
The failure I was referring to was not meant that the drug would not generate some revenue -- it will. However, if I recall Pharmasett, Gild, and all analysts were touting the drug as an ALL ORAL CURE FOR GENO 1. Obviously this press release indicates that is not the case. In that sense, in my book, their previous all oral claim for Geno 1, which in my judgment is the reason for its high pps, is a total failure.
Having said that, it won't surprise me if GILD pps continues going up because lots of investors have not really analyzed the data and wont for possibly quite a while. However, it remains to be seen if GILD's pps will continue to skyrocket like it has in the past once it becomes apparent that their magic drug for geno 1 is not any better than that of its competitors.